Ostarine may be the closest SARM to becoming accepted in medication and is particularly now in phase II clinical trials. Like SARMs on the whole, MK-2866 targets androgen receptors over a selective basis and avoids creating the kinds of destructive side effects involved with substances like testosterone, human growth hormone, https://garrisonq615yaa4.thenerdsblog.com/profile